Katalip (Fenofibrate)

Fenofibrate activates the nuclear receptor PPARα, leading to increased breakdown of triglyceride‑rich lipoproteins, reduced production of VLDL by the liver, and modest increases in HDL‑cholesterol, thereby improving the overall lipid profile.

The specific dose of Katalip is determined by the prescribing healthcare professional based on the patient’s clinical condition, laboratory results, and other individual factors. Patients should follow the prescriber’s instructions exactly.

Fenofibrate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to potential fetal risk. Safety during breastfeeding has not been established, and use is generally avoided.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Fenofibrate belongs to the fibrate class, which primarily lowers triglycerides and modestly raises HDL‑cholesterol. This differs from statins, which mainly reduce LDL‑cholesterol. In patients with high triglycerides or mixed dyslipidemia, fenofibrate may be preferred or used alongside a statin for complementary effects.

Katalip should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not store in extreme heat or humidity.

Katalip is taken orally, usually with a meal to improve absorption. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious risks include rhabdomyolysis (muscle breakdown that can lead to kidney failure), severe liver injury, gallstone formation, and rare cases of pancreatitis or life‑threatening allergic reactions. Patients should report unexplained muscle pain, dark urine, or jaundice promptly.

Katalip should not be used by individuals with known hypersensitivity to fenofibrate or other fibrates, patients with severe liver disease, those who are pregnant, or anyone taking contraindicated medications such as gemfibrozil without medical supervision.